TriangleDISEASE & TREATMENT SETTING
metastatic Ewing Sarcoma
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Treatment of Metastatic Ewing Sarcoma
Broader topic: Ewing Sarcoma
- Source population
- Not part of this definition
- Disease extent
- metastatic
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
- source wording
- Treatment of Metastatic Ewing Sarcoma
Study evidence for this setting
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATC
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice